A Phase 1/2 interventional study of AB1 in Sickle Cell Disease, sponsored by Nirmish Shah. Terminated at 3 sites in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Nirmish Shah · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.
Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 396th largest by enrollment of the 559 interventional ones that give a count, is one of 41 that started in 2022, is one of 60 in phase 1/2, and was the 580th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18–88
Mohsen Saidinejad · Sites in United States
Ages 5–20
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
Emory University · Sites in United States
Ages 8–18
University of Alabama at Birmingham · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
733 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 158 · Phase 2 228 · Phase 3 57 · Phase 4 20
First in 1984; this study’s year is marked. 41 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 31 across the 559 interventional studies, 100 across the 168 observational. Of the 506 that completed or were terminated, 209 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
168 of 733 have an industry lead sponsor. The 10 most frequent:
Nirmish Shah is the lead sponsor of 2 studies on the registry; none are open to participants now.
Nirmish Shah has 2 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
57 of the studies in Anemia, Sickle Cell with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07247188Phase 3SanofiStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | 2027-01-07 |
| NCT04293185Phase 3bluebird bioA Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease | 2027-05 |
| NCT06989567Phase 3Asklepion Pharmaceuticals, LLCA Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis | 2027-06 |
| NCT05329649Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | 2027-06-06 |
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
Add all 57 to your calendar (.ics) → With an account.
Among the 733 studies in Anemia, Sickle Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10mg, 12mg, 16mg, and 32mg. In each dose escalation cohort, each dose will be taken orally, once daily, for 8 weeks.
This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 4 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 16mg, and 32mg.
If there are any adverse events Grade ≥2 that are related (possibly, probably, or definitely) to study drug, at the 4mg cohort or in ≥2 patients in any subsequent cohort, the dose may be reduced to the previous cohort and an additional 3-6 patients (total of up to 9) may be enrolled into that cohort. Additionally, if Hbf levels increase >15% (expressed as a percentage of total Hb) in any cohort, the cohort can be expanded to an additional 3 to 6 patients as well as continue to the next cohort if safety parameters have been met. In the expansion cohort, patients will receive study drug treatment for an additional 4 weeks (total of 12 weeks)..
Approximately 6 to 39 patients may be enrolled for the entire study. Patients are eligible to enroll in a higher cohort of the study after a minimum of one-month washout from AB1 dosing, if their HbF levels return to baseline (\<15%) and the investigator deems the patient eligible.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AB1 is the investigational product in this study taken orally, once daily, for 8 weeks. This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg.
Drug: AB1
This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
Total Number of Adverse Events/Serious Adverse Events as Measured by Patient Report/Medical Records
Time frame: From the time of consent up to 12 months
Number of Participants With ≥Grade 2 Study Related Adverse Events as Measured by Patient Report/Medical Record
Adverse events that cause enough discomfort to interfere with usual daily activity; may warrant therapeutic intervention
Time frame: From the time of consent up to 12 months
Change in Cmax as Measured by Blood Test
Cmax is defined as the highest concentration a drug achieves in the bloodstream.
Time frame: Baseline, week 4, week 8, week 10
Change in Tmax as Measured by Blood Test
Tmax is defined as the time required to reach Cmax.
Time frame: Baseline, week 4, week 8, week 10
Change in T1/2 (Half Life) as Measured by Blood Test
T1/2 (half life) is defined as the time required for the plasma concentration of a drug to decrease by half during the elimination phase.
Time frame: Baseline, week 4, week 8, week 10
Change in AUC O-t as Measured by Blood Test
AUC o-t (Area Under the Curve from time zero to the last measurable concentration) measures a drug's total exposure in the bloodstream over a specific duration.
Time frame: Baseline, week 4, week 8, week 10
Change in Dose Normalized AUC O-inf as Measured by Blood Test
AUC o-inf (Area Under the Curve from time zero to infinity) is a vital metric that quantifies total drug exposure in the bloodstream. It represents the total amount of an administered drug that enters systemic circulation, from the moment it is given until it is completely eliminated from the body.
Time frame: Baseline, week 4, week 8, week 10
Change in Clearance (CL) as Measured by Blood Test
Clearance (CL) is the fundamental parameter measuring how efficiently the body removes a drug from systemic circulation. It represents the volume of plasma completely cleared of a drug per unit of time.
Time frame: Baseline, week 4, week 8, week 10
Change in Volume of Distribution (Vz) as Measured by Blood Test
Volume of distribution (Vz) represents the apparent volume of distribution during the terminal phase. It relates the amount of drug in the body to the plasma concentration specifically during the drug's elimination phase.
Time frame: Baseline, week 4, week 8, week 10
Change in Vss (Volume of Distribution at Steady State) as Measured by Blood Test
Vss (Volume of Distribution at Steady State) is a core pharmacokinetic parameter that defines the theoretical volume a drug would occupy if it were uniformly distributed at its steady-state concentration. It represents the actual blood and tissue volume the drug penetrates without being skewed by the terminal elimination phase.
Time frame: Baseline, week 4, week 8, week 10
Change in Percentage of Total Percentage of Total Hemoglobin (HB) as Measured by HPLC (High-Performance Liquid Chromatography)
Reported as the percent change from baseline to week 10.
Time frame: Screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12
Change in Percentage of F-cells Measured by Flow Cytometry
Reported as the percent change from baseline to week 10.
Time frame: Screening, baseline, week 2,week 4, week 6, week 8, week 10, week 12
Change in Percent Reticulocytes as Measured by Blood Tests
Time frame: Screening, baseline, week 2,week 4, week 6, week 8, week 10, week 12
| Milestone | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) |
|---|---|---|---|---|
| Started | 2 | 2 | 5 | 4 |
| Completed | 2 | 2 | 5 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
| adverse events | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) |
|---|---|---|---|---|
| Total Number of Adverse Events/Serious Adverse Events as Measured by Patient Report/Medical Records | 6 | 2 | 11 | 17 |
Adverse events that cause enough discomfort to interfere with usual daily activity; may warrant therapeutic intervention
| Participants | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) |
|---|---|---|---|---|
| Number of Participants With ≥Grade 2 Study Related Adverse Events as Measured by Patient Report/Medical Record | 1 | 1 | 2 | 3 |
Cmax is defined as the highest concentration a drug achieves in the bloodstream.
No measurements were reported for this outcome.
Tmax is defined as the time required to reach Cmax.
No measurements were reported for this outcome.
T1/2 (half life) is defined as the time required for the plasma concentration of a drug to decrease by half during the elimination phase.
No measurements were reported for this outcome.
AUC o-t (Area Under the Curve from time zero to the last measurable concentration) measures a drug's total exposure in the bloodstream over a specific duration.
No measurements were reported for this outcome.
AUC o-inf (Area Under the Curve from time zero to infinity) is a vital metric that quantifies total drug exposure in the bloodstream. It represents the total amount of an administered drug that enters systemic circulation, from the moment it is given until it is completely eliminated from the body.
No measurements were reported for this outcome.
Clearance (CL) is the fundamental parameter measuring how efficiently the body removes a drug from systemic circulation. It represents the volume of plasma completely cleared of a drug per unit of time.
No measurements were reported for this outcome.
Volume of distribution (Vz) represents the apparent volume of distribution during the terminal phase. It relates the amount of drug in the body to the plasma concentration specifically during the drug's elimination phase.
No measurements were reported for this outcome.
Vss (Volume of Distribution at Steady State) is a core pharmacokinetic parameter that defines the theoretical volume a drug would occupy if it were uniformly distributed at its steady-state concentration. It represents the actual blood and tissue volume the drug penetrates without being skewed by the terminal elimination phase.
No measurements were reported for this outcome.
Reported as the percent change from baseline to week 10.
| percentage of change | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) |
|---|---|---|---|---|
| Change in Percentage of Total Percentage of Total Hemoglobin (HB) as Measured by HPLC (High-Performance Liquid Chromatography) | 2.05 ± 0.85 | 1.30 ± 0.80 | 2.30 ± 0 | — |
Reported as the percent change from baseline to week 10.
| percentage of change | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) |
|---|---|---|---|---|
| Change in Percentage of F-cells Measured by Flow Cytometry | 1.60 ± 4.20 | 19.05 ± 18.55 | 4.95 ± 8.45 | — |
No measurements were reported for this outcome.
Collected over From the time of consent up to 12 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AB1 Treatment - 2 mg Dose (Cohort 1) | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| AB1 Treatment - 4 mg Dose (Cohort 2) | 0/2 (0%) | 1/2 (50%) | 1/2 (50%) |
| AB1 Treatment - 8 mg Dose (Cohort 3) | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| AB1 Treatment - 10 mg Dose (Cohort 4) | 0/4 (0%) | 3/4 (75%) | 4/4 (100%) |
| Event | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) |
|---|---|---|---|---|
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/2 | 0/2 | 0/5 | 0/4 |
| Vaso-Occlusive CrisisVascular disorders | 0/2 | 1/2 | 1/5 | 0/4 |
| Acute Infectious DiarrheaGastrointestinal disorders | 0/2 | 0/2 | 0/5 | 1/4 |
| Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)Investigations | 0/2 | 0/2 | 0/5 | 1/4 |
| Sickle Cell Pain CrisisBlood and lymphatic system disorders | 0/2 | 0/2 | 0/5 | 1/4 |
| E. Coli ColitisGastrointestinal disorders | 0/2 | 0/2 | 1/5 | 0/4 |
| Event | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) |
|---|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 1/2 | 1/2 | 0/5 | 1/4 |
| Mild NauseaGastrointestinal disorders | 1/2 | 0/2 | 0/5 | 0/4 |
| Intermittent Headaches Pain 9/10General disorders | 1/2 | 0/2 | 0/5 | 0/4 |
| Nausea with VomitingGastrointestinal disorders | 1/2 | 0/2 | 0/5 | 1/4 |
| DiarrheaGastrointestinal disorders | 0/2 | 0/2 | 0/5 | 2/4 |
| Intermittent FeverGeneral disorders | 0/2 | 0/2 | 0/5 | 1/4 |
| DehydrationGeneral disorders | 0/2 | 0/2 | 0/5 | 1/4 |
| Upper respiratory infection symptomsRespiratory, thoracic and mediastinal disorders | 0/2 | 0/2 | 0/5 | 1/4 |
| FatigueGeneral disorders | 0/2 | 0/2 | 1/5 | 1/4 |
| Stiff NeckMusculoskeletal and connective tissue disorders | 0/2 | 0/2 | 0/5 | 1/4 |
| Age, Continuous(years) | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) | Total |
|---|---|---|---|---|---|
| Mean | 29.50 ± 1.50 | 28.40 ± 4.00 | 29.40 ± 3.40 | 41.25 ± 8.26 | 32.85 ± 7.73 |
| Sex: Female, Male(Participants) | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) | Total |
|---|---|---|---|---|---|
| Female | 1 | 0 | 2 | 3 | 6 |
| Male | 1 | 2 | 3 | 1 | 7 |
| Ethnicity (NIH/OMB)(Participants) | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 2 | 5 | 4 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 | 4 | 12 |
| White | 0 | 0 | 1 | 0 | 1 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | AB1 Treatment - 2 mg Dose (Cohort 1) | AB1 Treatment - 4 mg Dose (Cohort 2) | AB1 Treatment - 8 mg Dose (Cohort 3) | AB1 Treatment - 10 mg Dose (Cohort 4) | Total |
|---|---|---|---|---|---|
| United States | 2 | 2 | 5 | 4 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2022 to primary completion in Oct 2024, 21 months.
Results were first posted in Oct 2026, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nirmish Shah